GSK's underperformance in Europe's Big Pharma stocks may attract activist investors due to expiring patents and declining vaccine sales. Analysts suggest strategic changes like successful M&A or pipeline progress to boost the share price. Previous activist pressures indicate potential shake-ups in GSK's business strategy for improved performance.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay